en · de · es · fr · pt
thymosin-alpha-1-notes.peptides4800.com › Wiki › Background And Mechanism Of Action — Evidence Review

Background And Mechanism Of Action — Evidence Review

By Editorial Desk · published 2025-10-31 · last reviewed 2025-12-01 · Wiki

thymalfasin raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.

Reviewed 2025-12-01. Anything still debated is marked as such rather than presented as settled.

Background and Mechanism of Action

Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.

Thymosin alpha-1 is a synthetic 28-amino-acid peptide whose sequence was first identified in extracts of bovine thymus tissue during the 1970s. The chain carries an acetyl group on its N-terminal serine. Its acidic residue content is high, which produces strong water solubility and an isoelectric point well below neutrality. Material supplied for laboratory and clinical use is manufactured by solid-phase peptide synthesis rather than purified from animal tissue. Different salt forms, such as the acetate, alter the counter-ion content without changing the peptide backbone.

Whether the free 28-residue peptide circulates in human tissue remains debated. The best-documented human source is prothymosin alpha, a larger acidic protein that carries the sequence at its N-terminus. Reports of measurable peptide levels in serum and lymphoid tissue exist, yet some of that signal may come from cross-reacting fragments or from the parent protein. Most reviews therefore treat prothymosin alpha as the established human molecule and describe independent circulation of the small peptide as an unresolved question.

Molecular Background and Identity

Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.

Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.

Thymosin-alpha-1 at a glance

PropertyValueNotes
Amino acid length28 residuesSingle chain with an acetylated N-terminus
Molecular massApproximately 3,108 DaSmall shifts occur with counter-ion and water content
Isoelectric pointAround 3.5Low value follows from the many acidic residues
Parent moleculeN-terminal region of prothymosin alphaFree circulating form in humans is not firmly established
Common synonymsThymalfasin; T alpha 1Older literature also uses the full spelled-out form

分子身份与天然来源

市售的胸腺素α1通常以冻干粉形式提供,溶解后用于注射。其氨基酸组成包括多个酸性残基,因此在中性pH下带负电荷。该肽可溶于水和生理盐水,但在有机溶剂中溶解度有限。储存条件通常为冻干状态下负20摄氏度,溶解后需冷藏并避免反复冻融。常见的同义词包括胸腺肽α1、thymalfasin和Tα1。

胸腺素α1(thymosin alpha 1,Tα1)是一种由28个氨基酸组成的酸性肽,N端被乙酰化,分子量约为3108道尔顿。该肽最早从牛胸腺组织提取物中分离,属于胸腺素组分5的一个成分。其序列在不同哺乳动物中高度保守,提示其具有基本的生物学功能。名称中的“α1”指其在电泳中的迁移位置,并非表示亚型编号。它既存在于胸腺,也存在于脾脏和淋巴结等免疫组织。

Related pages on this site

Background, Structure, and Mechanism

Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.

Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.

Notes from published material

=== Epilepsy === As an adjunctive therapy in epilepsy, it is used in patients who have not responded to first-line drugs and in children who are refractory to first-line drugs. It is unclear if there are any benefits to clobazam over other seizure medications for children. It is not recommended for use in children between the ages of six months and three years, unless there is a compelling need. Clobazam is approved in Canada (Frisium) for add-on use in tonic–clonic, complex partial, and myoclonic seizures. Clobazam is approved for adjunctive therapy in complex partial seizures, certain types of status epilepticus, specifically the myoclonic, myoclonic-absent, simple partial, complex partial, and tonic varieties, and non-status absence seizures. In the United States, clobazam (Onfi) was not marketed until October 2011 and was only approved for use in combination with other medications to control epilepsy in people aged two years of age and older who have Lennox–Gastaut syndrome.

Paclitaxel, an alkaloid derived from the Pacific yew, and sold under the brand name Taxol among others, is a chemotherapy medication used to treat ovarian cancer, esophageal cancer, breast cancer, lung cancer, Kaposi's sarcoma, cervical cancer, and pancreatic cancer. It is administered by intravenous injection. There is also an albumin-bound formulation. Common side effects include hair loss, bone marrow suppression, numbness, allergic reactions, muscle pains, and diarrhea. Other side effects include heart problems, increased risk of infection, and lung inflammation. There are concerns that use during pregnancy may cause birth defects. Paclitaxel is in the taxane family of medications. It works by interference with the normal function of microtubules during cell division. Paclitaxel was isolated in 1971 from the Pacific yew and approved for medical use in 1993. It is on the World Health Organization's List of Essential Medicines. It has been made from precursors, and through cell culture.

Herein, the total number of carbons about the fatty acid is listed prior to the total number of double bonds present within the molecule, and is generally formatted as is seen in Example 1. for palmitic acid (C16:0) and palmitoleic acid (C16:1).

== Accidents and incidents == As of August 2013, the Il-86 is known to have been involved in at least 10 incidents, including 4 hull losses with a total of 23 fatalities unrelated to passengers. During its passenger-carrying operations the Il-86 has not been involved in any fatal accident. The following are reported significant recorded safety events involving the Il-86:

Sources: en.wikipedia.org

Further detail

Shulman proposed that lipid-induced insulin resistance results from the accumulation of sn-1,2-diacylglycerol (DAG) in the plasma membrane, which activates novel protein kinase C (nPKC) isoforms—PKCθ in skeletal muscle and PKCε in liver and white adipose tissue—impairing insulin signaling. Shulman's lab explored interventions such as weight loss, thiazolidinediones, adiponectin, leptin, and liver-targeted mitochondrial protonophores to reverse insulin resistance by lowering plasma membrane DAG and inhibiting the nPKC pathway. He also pioneered 13C and 31P NMR methods to measure ATP synthesis and mitochondrial oxidation in vivo. His team identified age-related declines in mitochondrial fat oxidation linked to insulin resistance in elderly individuals, and in insulin-resistant offspring of people with T2D. They showed that chronic AMPK activation drives mitochondrial biogenesis via increased expression of PGC-1α. Shulman used 13C NMR to quantify rates of hepatic glycogenolysis and gluconeogenesis, showing that the latter accounts for over half of fasting hepatic glucose production following an overnight fast overturning the Cahill hypothesis that hepatic glycogenolysis accounts for >90% of glucose production in humans following an overnight fast.

==== Vitamin K ==== Vitamin K is an essential factor to the hepatic gamma-glutamyl carboxylase that adds a carboxyl group to glutamic acid residues on factors II, VII, IX and X, as well as Protein S, Protein C and Protein Z. In adding the gamma-carboxyl group to glutamate residues on the immature clotting factors, Vitamin K is itself oxidized. Another enzyme, Vitamin K epoxide reductase (VKORC), reduces vitamin K back to its active form. Vitamin K epoxide reductase is pharmacologically important as a target of anticoagulant drugs warfarin and related coumarins such as acenocoumarol, phenprocoumon, and dicumarol. These drugs create a deficiency of reduced vitamin K by blocking VKORC, thereby inhibiting maturation of clotting factors. Vitamin K deficiency from other causes (e.g., in malabsorption) or impaired vitamin K metabolism in disease (e.g., in liver failure) lead to the formation of PIVKAs (proteins formed in vitamin K absence), which are partially or totally non-gamma carboxylated, affecting the coagulation factors' ability to bind to phospholipid.

=== Recording of examination === The patient's dentition is divided into six sextants – three sextants for the mandible and maxillary respectively. All teeth, except the 3rd molars, are examined (note the 3rd molars are included if there are no other molars in that sextant). The sextants include: Upper Right (17 to 14) Upper Anterior (13 to 23) Upper Left (24 to 27) Lower Right (47 to 44) Lower Anterior (43 to 33) Lower Left (34 to 37) For a sextant to be recorded, at least two teeth must be present. Otherwise, the lone standing tooth will be included with the recordings of the adjacent sextant.

=== Liver and kidney failure === The drug should be used with caution in those with liver or kidney failure, due to metabolism in the liver (to the active molecule desmetramadol) and elimination by the kidneys.

Dinosaurs are a diverse group of warmblooded reptiles of the clade Dinosauria. They existed through most of the Mesozoic era, first appearing early in the Triassic period. They became the dominant terrestrial vertebrates after the Triassic–Jurassic extinction event 201.3 mya and their dominance continued throughout the Jurassic and Cretaceous periods. The fossil record shows that birds are feathered dinosaurs, having evolved from earlier theropods during the Late Jurassic epoch, and are the only dinosaur lineage known to have survived the Cretaceous–Paleogene extinction event approximately 66 mya. Dinosaurs can therefore be divided into avian dinosaurs—birds—and the extinct non-avian dinosaurs, which are all dinosaurs other than birds. Dinosaurs are varied from taxonomic, morphological and ecological standpoints. Birds, at over 11,000 living species, are among the most diverse groups of vertebrates. Using fossil evidence, paleontologists have identified over 900 distinct genera and more than 1,000 different species of non-avian dinosaurs. Dinosaurs are represented on every continent by both extant species (birds) and fossil remains. Through most of the 20th century, before birds were recognized as dinosaurs, most of the scientific community presumed dinosaurs to have been sluggish and cold-blooded. Most research conducted since the 1970s, however, has indicated that dinosaurs were active animals with elevated metabolisms and numerous adaptations for social interaction.

Sources: en.wikipedia.org

Supporting material

=== Fictional character biography === James Howlett was born near Cold Lake in Alberta, Canada, during the late 19th century to rich farm owners John and Elizabeth Howlett. However, James was actually the result of an extramarital affair between Elizabeth and the family's groundskeeper Thomas Logan. Thomas was also the father of Dog Logan, James's half-brother. Thomas became increasingly unstable because of his drinking, lost his job, and was expelled from the Howlett manor. He returned to the manor and killed John Howlett. In retaliation, James killed Thomas with bone claws that emerged from the back of his hands, as his mutation manifested. He fled with his childhood companion, Rose, and grew into manhood on a mining colony in Yukon, adopting the name "Logan". When Logan accidentally killed Rose with his claws, he fled the colony and lived in the wilderness among wolves. Logan then resided with the Blackfoot people. Sabretooth apparently killed Logan's Blackfoot lover, Silver Fox. Logan joined the Canadian military during World War I, and then became a career soldier. During World War II, Logan teamed up with Captain America. He spent time in Madripoor before settling in Japan, where he married a civilian, Itsu. While Logan was away from home, Romulus sent the Winter Soldier to kill the pregnant Itsu and had her baby taken from her womb. While Logan believed his son to be dead, the child was taken and given the name Daken. Wolverine later worked for the Central Intelligence Agency before being recruited by Team X, a black ops unit.

=== Seizures === Phenobarbital is used in the treatment of all types of seizures, except absence seizures. It is no less effective at seizure control than phenytoin, but phenobarbital is not as well tolerated. Phenobarbital may provide a clinical advantage over carbamazepine for treating partial seizures. Carbamazepine may provide a clinical advantage over phenobarbital for generalized tonic–clonic seizures. The first-line drugs for treatment of status epilepticus are benzodiazepines, such as lorazepam, clonazepam, midazolam, or diazepam. If these fail, then phenytoin may be used, with phenobarbital being an alternative in the US (favored in infants), but used only third-line in the UK. Failing that, the only treatment is anesthesia in intensive care. The World Health Organization (WHO) gives phenobarbital a first-line recommendation in the developing world and it is commonly used there. Phenobarbital is the first-line choice for the treatment of neonatal seizures. Concerns that neonatal seizures in themselves could be harmful make most physicians treat them aggressively. However, no reliable evidence supports this approach.

Governor William Robinson shared the same view with the former, insisted that a Medical Department with a Principal Civil Medical Officer directly under the Government should replace the Sanitary Board. With regard of the reconstitution of the Sanitary Board, Governor William Robinson conducted a plebiscite in June 1896. Besides the reconstitution of the Sanitary Board issues, in 1894 there was a group of petitioners supported by the Unofficial Members of the Legislative Council Paul Chater and Ho Kai with 363 signatures asked for a further representations in the Colonial Government. They demanded:

In November 1953, Florey was informed that works would proceed as planned. On 27 March 1958, Florey ceremoniously opened the John Curtin School of Medical Research and received an honorary Doctor of Science degree along with Sir Norman Gregg. Menzies, Coombes, Ennor and Curtin's family were in attendance. This was not the end of Florey's association with the ANU. In 1964, he accepted the role of chancellor, a position he held from 1965 until his death in 1968.

Sources: en.wikipedia.org

Frequently asked questions

Is thymosin alpha-1 a hormone?

It is usually described as an immunomodulatory peptide rather than a classic circulating hormone. No endocrine gland is known to release it as a primary secretory product, and its measured presence in blood is not firmly established.

How does it relate to prothymosin alpha?

Prothymosin alpha is a much larger acidic protein, roughly 111 to 113 residues long, and the thymosin alpha-1 sequence matches its N-terminal region. The small peptide is therefore best understood as a fragment of that parent protein rather than a separate gene product.

Which clinical areas have been studied?

Trials and clinical reports have examined chronic hepatitis B and C, use as a vaccine adjuvant, and supportive treatment in some immunodeficiency and oncology settings. Results vary by indication, and regulatory approval differs between countries.

Is thymosin alpha 1 a hormone?

The name reflects an early convention for naming thymus-derived fractions. The peptide is characterized and measured as a defined molecule, and it does not operate through a single classical endocrine axis.

Network